Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach

Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing

(2010) Kay Stubenrauch et al.   CLINICAL THERAPEUTICS

Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis

(2010) Benoit Le Goff et al.   JOINT BONE SPINE

Target-mediated drug disposition model for drugs that bind to more than one target

(2010) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 as a key player in systemic inflammation and joint destruction

(2009) J.E. Fonseca et al.   AUTOIMMUNITY REVIEWS

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

(2009) Leonid Gibiansky et al.   Expert Opinion on Drug Metabolism & Toxicology

Target-mediated drug disposition model: relationships with indirect response models and application to population PK–PD analysis

(2009) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models

(2009) Xiaoyu Yan et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET